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Introduction: Cystinosis is a rare systemic lysosomal storage disease that mainly affects the
kidney and the eye. Renal replacement therapy is started in patients with cystinosis during
the ﬁrst decade of life in the absence of treatment. The prognosis of cystinosis depends on
early diagnosis and the prompt start of and good compliance with cysteamine treatment.
Kidney disease progression, extra-renal complications and shorter life expectancy are more
pronounced in patients who do not adhere to treatment.
Transition
Adherence
Objective: The aim of this work was to establish recommendations for the comprehensive
care of cystinosis and facilitate patient transition from paediatric to adult medicine, based
on clinical experience. The goal is to reduce the impact of the disease and improve prognosis
and patient quality of life.
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Methods: Bibliographic research and consensus meetings with a multidisciplinary profes-
sional team of clinical experts in cystinosis (T-CiS.bcn group) from 5 hospitals in Barcelona.
Results: This consensus document gathers speciﬁc recommendations for the diagnosis,
treatment and multidisciplinary care of cystinotic patients in the following areas: nephrol-
ogy, dialysis, kidney transplantation, ophthalmology, endocrinology, neurology, laboratory,
genetic counselling, nursing and pharmacy.
Conclusions: Guidelines for the comprehensive care of cystinosis provide a support tool for
health professionals who look after these patients. They are based on the following main
pillars: (a) a multidisciplinary approach; (b) appropriate disease monitoring and control of
white blood cell (WBC) cystine levels; (c) the importance of adherence to cysteamine treat-
ment; and (d) the promotion of patient self-care bymeans of disease education programmes.
All these recommendations will lead us, in a second phase, to create a coordinated model
of transition from paediatric to adult care services which will cover the speciﬁc needs of
cystinosis.
© 2014 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cistinosis en pacientes adolescentes y adultos: recomendaciones para la
atención integralde la cistinosis
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Introducción: La cistinosis es una enfermedad lisosomal minoritaria de expresión sistémica
con especial afectación renal y oftalmológica, en la que los pacientes inician terapia renal
sustitutiva en la primera década de la vida en ausencia de tratamiento. El pronóstico de
la cistinosis depende del diagnóstico precoz, la pronta instauración del tratamiento con
cisteamina y el buen cumplimiento terapéutico. La progresión de la enfermedad renal y
de las complicaciones extrarrenales y una menor supervivencia, son más acentuadas en
pacientes no adherentes.
Objetivo: El objetivo de este trabajo fue la elaboración de unas recomendaciones para la
atención integral de la cistinosis y la transición del adolescente a la medicina del adulto,
basadas en la experiencia clínica, con el ﬁn de reducir el impacto de la enfermedad ymejorar
la calidad de vida y el pronóstico del paciente.
Método: Búsqueda bibliográﬁca y reuniones de consenso de un equipo multidisciplinar de
expertos en la práctica clínica con pacientes afectos de cistinosis (Grupo T-CiS.bcn), proce-
dentes de 5 hospitales localizados en Barcelona.
Resultados: El documento recoge recomendaciones especíﬁcas y necesarias para el diagnós-
tico, tratamiento y seguimiento multidisciplinar de la cistinosis en las siguientes áreas:
nefrología, diálisis, trasplante renal, oftalmología, endocrinología, neurología, laboratorio,
consejo genético, enfermería y farmacia.
Conclusiones: Disponer de un documento de referencia para la atención integral de la cisti-
nosis constituye una herramienta de soporte para los profesionales de la salud que asisten
a estos pacientes. Los principales pilares en los que se sustenta son: a) el enfoque mul-
tidisciplinar, b) la adecuada monitorización de la enfermedad y control de los niveles de
cistina intraleucocitarios, c) la importancia de la adherencia al tratamiento con cisteam-
ina y d) la promoción del autocuidado del paciente mediante programas de educación en
la enfermedad. Todo ello conducirá, en una segunda fase, a la elaboración de un modelo
de transición coordinado entre los servicios de pediatría y de adultos que contemple las
necesidades especíﬁcas de la cistinosis.
© 2014 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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tntroductionystinosis is a rare systemic lysosomal storage disease
hich, if not treated, leads to end-stage kidney failure in
he ﬁrst decade of life.1 Its natural history has been trans-(http://creativecommons.org/licenses/by-nc-nd/4.0/).
formed thanks to the development of kidney transplantation
(KTx) in children2 and the availability of speciﬁc treatment
with cysteamine, a drug therapy that should be maintained
throughout the patient’s lifetime.3 As a consequence, patient
survival has increased from the ﬁrst decade of life to beyond
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the fourth decade and cystinosis has passed from paediatrics
to adult medicine.4
The control of cystinosis is complex owing to its severity
and multisystemic nature, and the requirement of treatment
with several drugs with a very strict dosage schedule. Early
diagnosis, prompt cysteamine administration and treatment
adherence inﬂuence morbidity and prognosis.5,6 Neverthe-
less, adherence to therapy, which is usually good in children,
tends to wane in teenagers and adults.7 Furthermore, when
patients reach adult age, they are usually transferred from
the paediatric expert centre to a local hospital with limited
experience in cystinosis, while the systemic manifestations
continue to progress and the disease becomesmore complex.8
This phenomenon is seen in other chronic renal diseases that
debut in paediatric patients9 and highlights the need to imple-
ment transition strategies and promote patient self-care.10
The current cystinosis count in Spain comprises 56patients
treated and followed up at 22 hospitals. Approximately 50%
are adults and 16% adolescents; 57% are kidney transplant
recipients.7
The working group for the care and transition of cystinosis
in Barcelona (T-CiS.bcn) has assembled a group of experts in
the disease to establish, as a ﬁrst step, recommendations for
the comprehensive care of cystinosis and the transitionof ado-
lescents to adult-care units in our country. This consensus
document presents a support tool for health care profession-
als both involved in and interested in cystinosis. It is focused
on reducing disease impact, improving quality of life and pro-
longing survival, in accordance with the guidelines of the
International Society of Nephrology (ISN) and the Interna-
tional Paediatric Nephrology Association (IPNA).10 At a later
date, the T-CiS.bcn group plans to create a coordinated model
of transition from paediatric to adult care services which will
cover the speciﬁc needs of cystinosis.
Etiopathogenesis
Cystinosis is a hereditary autosomal recessive disease caused
by mutations with loss of function of the CTNS gene (chro-
mosome 17p13), which encodes for cystinosin.11 Cystinosin
is a speciﬁc transmembrane protein for the transport of
cystine from the lysosome to cell cytoplasm.12 Its absence
causes progressive deposits of intralysosomal cystine, the
main diagnostic marker of the disease1. Its annual inci-
dence is estimated at 1/100,000–200,000 newborns, while
the population prevalence is 1–9/1,000,000.13 The most fre-
quent mutation in the CTNS gene is a deletion of 57Kb14
which is also observed in 34% of patients in the Spanish
population.15
The amino acid cysteine oxidises inside the lysosome and
forms cystine. In patients with cystinosis, there is an accu-
mulation of cystine that precipitates in crystal form in all the
cells of the organism, particularly in renal and ocular tissue.16
The increase in the lysosomal concentration of cystine is
associated with increased cellular apoptosis, oxidative stress
and alterations in the metabolism of glutathione and arachi-
donic acid.17–19 Other pathogenic mechanisms involved are
inﬂammatory20 and “endoplasmic reticulum stress”, which
ﬁnally lead to cell death.21,22;35(3):304–321
Symptoms
Cystinosis is a multisystemic disease23 with the kidneys and
eyes being the ﬁrst organs to be affected. Three clinical
forms have been described: infantile nephropathic cystinosis
(OMIM#219800), the most serious subtype, which debuts early
on; juvenile nephropathic cystinosis (OMIM#219900), a less
severe subtype, which debuts in childhood or later; and adult
non-nephropathic cystinosis (OMIM#219750), with exclusively
ocular involvement.24 Nonetheless, in clinical practice, two
main subtypes are deﬁned: nephropathic cystinosis that
debuts in early childhood with severe Fanconi syndrome (rep-
resenting 95% of all cases) and late-onset non-nephropathic
cystinosis, which appears in young patients or adults with
renal and/or ocular involvement (representing <5% of affected
patients). In some patients, ocular involvement can precede
renal manifestations by several years.25
Renal disease
Fanconi syndrome
Typical clinical symptoms include the appearance of severe
Fanconi syndrome with evolution to chronic kidney disease
(CKD) (Fig. 1). Tubulopathy characteristically becomes evident
in the second semester of life after a symptom-free interval.24
Affected newborns are apparently normal, although it is
possible to detect urinary alterations (alkalineurine with gly-
cosuria and/or proteinuria) very early preceding symptoms.26
Cystinosis is the most frequent cause of inherited Fanconi
syndrome24 and should be considered in the initial differ-
ential diagnosis in newborns. Nonetheless, cases have been
described of cystinotic patients who debuted with atypical
symptoms not suggestive of Fanconi syndrome but of distal
tubulopathy, such as nephrogenic diabetes insipidus or Batter
syndrome. Thus, the diagnosis of cystinosis should be consid-
ered in all newborns with complex tubulopathy, particulary if
growth is affected and the patient is anorexic.1 The differen-
tial diagnosis should contemplate the possibility of secondary
proximal tubulopathy.27,28 The severity of Fanconi syndrome
associated with cystinosis requires rigorous treatment that is
frequently very complex (Table 1).
Chronic kidney disease
After the age of two, if no speciﬁc treatment is administered,
glomerular involvement progress with a drop in the glomeru-
lar ﬁltration rate (GFR) and an increase in plasma creatinine
starting at the age of 4 to 6, which evolves to advanced CKD.1
Concurrently, Fanconi syndrome usually remits and, conse-
quently, it is possible to reduce water/electrolyte supplements
(Table 1). In the absence of speciﬁc pharmacological treatment
(cysteamine), mean age at the onset of end-stage renal dis-
ease (ESRD) is 9.2 years. Inmore contemporary series including
patients who received early treatment with cysteamine, there
is a signiﬁcant delay in evolution to ESRD at the age of 13.5
which has been attributed to better patient control by physi-
cians. Furthermore, in cases with very early diagnosis and
treatment, there is a growing percentage of patients who
remain in predialysis after adolescence.6
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dig. 1 – Clinical manifestations of cystinosis in patients not
nd stage renal disease, RRT: renal replacement therapy.
There are also forms of attenuated or late-onset cysti-
osis that debut in adolescence or in young adults, such
s glomerular disease and proteinuria without Fanconi syn-
rome, although occasionally signs suggestive of proximal
ubulopathy are observed. Usually, patients also present
cular manifestations of the disease that can be nearly
symptomatic25 (Fig. 1).
Although renal biopsy is not necessary for diagnosis, it
emonstrates non-speciﬁc lesions of glomerulosclerosis and
ther more characteristic signs such as irregularities on the
rush border of proximal tubule cells, swan neck deformity
nd, occasionally, deposits of cystine crystals and giant mult-
nucleated podocytes.2,16,24
ialysis
he renal replacement therapy (RRT) of choice in cystinosis is
he kidney transplantation (KTx) since the disease does not
ecur in kidney grafts. In many cases, however, the limitation
f organs or delayed diagnosis results in the start of dialysis.
ccording to the NAPRTCS register, 1.4% of patients <18 years
f age who initiated chronic dialysis had cystinosis.30 On the
ther hand, in the European ESPN/ERA-EDTA Registry, 0.9%
f patients <20 years of age and 0.1% of patients >20 years
ithRRThadcystinosis. In Europe, peritoneal dialysis (PD)was
he most frequent initial treatment modality (39.6%), followed
y preventive KTx (35.1%). Some 17.9% of patients received
5aemodialysis (HD).
Fanconi syndrome can persist after the start of dialysis,
hich inﬂuences the dietetic prescription for water, patient
iet and the possible need to administer other medicationsed with cysteamine. CKD: chronic kidney disease, ESRD:
such as phosphorus chelates. Although the urinary loss of
saline and polyuria usually decrease in advanced CKD, the
patient may continue to need water/electrolyte supplements
and carnitine (Table 1). On rare occasions, the severity of Fan-
coni syndrome justiﬁes nephrectomy of the native kidneys.31
Moreover, many cystinotic patients on dialysis characteristi-
cally present extrarenal involvement requiring the integrated
intervention of other specialists (see section on extrarenal
involvement), which can be a challenge for nephrologists
when treating their patients.32
Kidney transplantation
As previously stated, the RRT of choice in cystinosis is KTx.
Since graft cells do not carry the lysosomal defect, the disease
does not recur in the transplanted organ. However, it is pos-
sible to observe interstitial deposits of cystine crystals, which
represent leukocytes of the recipient and have no pathological
signiﬁcance.21 Family-donor transplantation is also curative,
and heterozygous carriers of the CTNS mutation can be
appropriate donors since they do not have the disease.4,6,33
Indirect data from cystinotic patients with advanced
kidney failure and international registries suggest that
preventive kidney transplantation would be beneﬁcial in
this disease, particularly when a living donor is available4
thereby avoiding the need for dialysis.5 Thus, the indication
for kidney transplantation is established when the GFR is
2<20ml/min/1.73m , which would be somewhat earlier than
in other kidney diseases.1
In the United States (USRDS2013), mean age of patients
with cystinosis at the ﬁrst KTx is 13.8 years (range: 2 to 24),
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Table 1 – Symptomatic treatment of renal disease in
cystinosis.1,24,29,31
Therapeutic aims Treatment
Preserve water balance by
replacing losses
Replace water loss according to
need (between 1.5 and 6L/day),
either orally or by nasogastric tube
or gastrostomy, if needed.
Reduce polyuria: oral
indomethacin (1–3mg/kg/day)
Preserve electrolyte balance
by replacing losses
Potassium (between 2 and
10mEq/kg/day)
ClNa (1–2mEq/kg/day, with
progressive increase in dosage)
Phosphorus (between 1 and
4g/day)
Neutralise acidosis
(maintain normal blood
pH and serum
bicarbonate between 22
and 24mEq/L)
Bicarbonate or citrate at an initial
dose of 1–2mEq/kg/day, with
progressive increase in dosage
Nutritional support Nutritional assessment with
appropriate caloric
supplementation according to age
and kidney function
Treatment of bone mineral
disease
Cholecalciferol
Calcium supplements
Active vitamin D (1 Alpha-vitamin D,
Calcitriol, Paricalcitol, others)
Growth hormone (if indicated)
Others Carnitine29 (100mg/kg/día)
ACEi/ARB antiproteinuric agents
(assess tolerance)
tine crystals, mineral deﬁciency, renal rickets and CKD perACEi/ARB: inhibitors of the renin-angiotensin system.
which has not changed in recent decades; 32.4% underwent
preventive KTx.34 Similarly data from the European Registry
(ESPN/ERA-EDTA Registry) show a similar percentage of 35.1%
predialysis transplantations, a much higher percentage than
in other nephropathies (17.1%).5 Eighty-ﬁve percent of all the
cystinotic patients in RRT were kidney transplant recipients.
Regarding the type of donor, 54% of patients in the US received
a living and 46%a deceased donor organ.34 Similarly, in Europe
48.9% received a living donor transplant.5
It isworthy ofmention that the duration of functioning kid-
ney grafts in cystinotic patients is longer than that observed in
the population of recipients transplanted for other causes.5,35
Extrarenal disease
The longer survival and better prognosis of patientswith cysti-
nosis have resulted in better understanding of the multiple
organ involvement in this disease4,6,32,36 (Fig. 1).
Ocular involvement
Eye involvement is intrinsic to cystinosis. The presence of cys-
tine crystals in the cornea is a diagnostic criterion for this
disease,37 although its absence before the age of 12 months
may not rule it out.1;35(3):304–321
Cystine deposits in the cornea are one of the earliest
manifestations of cystinosis (Fig. 1). Although no crystals are
present at birth, they can be observed in children who are only
a few months old.1 Initially, they are deposited in the super-
ﬁcial layers of the peripheral cornea, but progressively begin
to affect all the layers and entire extension of the cornea. If
left untreated, corneal crystal deposits progress inexorably,
increasing with age, resulting in photophobia, which can be
quite incapacitating, and in abnormal corneal sensitivity. In
time, this condition leads to recurrent corneal erosions and
stromal oedema, which can reduce visual acuity. Reports also
exist of calcium deposition in Bowman’s membrane or band
keratopathy, which affect vision when situated in the visual
axis.37
Crystals are also deposited in other ocular structures
such us the conjunctiva, anterior chamber, iris, ciliary body,
choroid and retina. Retinal involvement causes degenera-
tion of the photoreceptors, mainly the rods, thereby altering
the peripheral visual ﬁeld and night vision, although central
vision may also be reduced. Less frequently, there have been
reports of posterior synechiae, adherence of the iris to the
anterior lens capsule and neovascularisation of the periph-
eral cornea.38,39 Furthermore, tear production is reduced,
causing dry eye, and neuro-ophthalmological manifestations
(papilledemaandophthalmoplegia) are observed secondary to
the increased intracranial pressure reported in this disease.4
In late-onset disease, the presence of crystals might not be
detected until adulthood.25
Growth and development: mineral-bone involvement
Failure to thrive is a classic clinical symptom of cystinosis
and frequently is the reason for an early consultation.36 The
underlying mechanism is multifactorial, although it is related
to Fanconi syndrome severity. The concurrence of metabolic
acidosis, hyponutrition, increased gastrointestinal and renal
losses and CKD lead to delayed growth that can be very
severe.40,41 Similarly, patients present endocrine alterations
(see endocrine involvement section) and, infrequently, pri-
mary growth hormone (GH) deﬁciency.42
Patients with inadequate treatments usually have shorter
stature.36 Classically, the adult height reported in patients
with suboptimal treatment is 144 cm and weight 45kg (25 cm
and 25kg below the normal population average, respectively).4
The most recent series with better therapeutic control
reported less retarded growth8 and a favourable impact of
treatment on growth regulation mechanisms.43 Nevertheless,
nowadays 27% of transplanted cystinotic patients and 44% of
those on dialysis continue to be shorter than average.5
Early GH administration improves height and weight,
although the therapeutic response is usually lower than that
observed inCKDdue to other causes, despite optimumdisease
control. GH is an essential therapeutic tool in this disease, for
its impact on longitudinal growth and its anabolic effect.40,44
Patients with cystinosis develop a characteristic metabolic
bone disease caused by different factors: bone deposits of cys-
24se.45 Bone anomalies attributed to copper deﬁciency, possibly
secondary to Fanconi syndrome have also been described.46 It
is therefore common to detect osteopenia, especially in trans-
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lant recipients, related also to other endocrine alterations of
he disease (see endocrine involvement section) and poten-
ially to the treatment.23,47 Some patients have bone fragility
nd a higher risk of fractures.32
ndocrine involvement
ndocrine manifestations are caused by destruction of the
ffected glands due to cystine deposits; their incidence and
ge at appearance are associated with the establishment of
peciﬁc treatment with cysteamine.43
Primary hypothyroidism is the most frequent endocrine
omplication;23 it is progressive and requires chronic treat-
ent with levothyroxine.1,4 Diabetes mellitus (DM) is char-
cterised by a progressive alteration in insulin secretion,48
ith negative immunology, and requires treatment with
nsulin.2 It is observed in transplant recipients who receive
orticosteroids.23 In males, cystinosis causes primary hypog-
nadism and infertility is a constant.4,49 In females, however,
either hypogonadism nor infertility are prevalent, and
ffected patients can thus have children,50 although the risk
f prematurity is increased.51
ardiovascular involvement
he appearance of dyslipidemia and vascular calciﬁcation
ue to cystinosis and CKD are considered increased cardio-
ascular risk factors.23,32,41 42% of patients develop arterial
ypertension, usually post-transplantation. Aortic aneurysms
nd coronary vessels involvement, as well as cardiomyopathy
ssociated with cystine crystals deposits in the myocardium
ave also been reported.36 In adult patients, screening for
schaemic heart disease is recommended.4
eurological involvement
ystinosis is associated with alterations in cerebral structure
nd increased cystine levels in different areas of the nervous
ystemandmuscle tissue.4,6,32,52 In general, neurological com-
lications worsen the prognosis of the disease:
Progressive ischaemicmyopathy4,32,53 is predominantly dis-
tal and begins in the hands; loss of muscle mass is
also observed with later ventilator capacity impairment
and swallowing difﬁculties. Some authors attribute muscle
weakness in these patients to carnitine deﬁciency.24,28,29
Central nervous system (CNS) involvement4,31 is mainly
observed in patients with suboptimal treatment with cys-
teamine:
– Acute presentation: epilepsy, stroke, encephalopathy,
cephalalgia54–57
– Subacute/progressive presentation: intracranial hyper-
tension, cerebral atrophy, ataxia, pyramidalism, gait
disorders, basal and periventricular lymph node cal-
ciﬁcations, demyelination of white matter, mental
deterioration58–66
Neurocognitive alterations:67–73 in cystinotic patients, a spe-
ciﬁc proﬁle of alterations in visual-motor integration, visual
memory, maintained attention, planning, motor processing
speed and arithmetic calculation have been described. Con-
sequently, they account for a signiﬁcant incidence of social(3):304–321 309
difﬁculties that could explain the behavioural phenotype in
some patients. Intelligence is usually normal.
Early detection of neurological complications in cystinosis
facilitates better therapeutic strategies, reduces the number of
hospitalisations and improves quality of life. The participation
of a neurologist will help to evaluate the functional capacity
of patients and detect earlier the neurological manifestations
that can affect autonomy in basic daily life activities.8,31,32,55
Miscellaneous
The ubiquity of cystinosis is demonstrated by its non-speciﬁc
symptoms e.g. gastrointestinal and other disorders such as
heat intolerance and hypophoresis. Similarly, the systemic
nature of the disease explains the progressive appearance of
other clinical symptoms secondary to the deposition of cys-
tine crystals in different organs and systems, as detailed below
(Fig. 1):
• Digestive system74:
– Nausea, vomiting, epigastralgia, anorexia
– Increased gastrin secretion (associated with taking cys-
teamine)
– Decreased salivation
– Mechanical swallowing difﬁculties
– Delayed gastric emptying and intestinal and intestinal
dysmotility
– Intestinal pseudo-obstruction
– Intestinal inﬂammatory disease
• Liver32,75:
– Regenerative nodular hyperplasia without liver failure
– Non-cirrhotic portal hypertension with hypersplenism
– Cholestasis
– Hypercholesterolemia
• Skin1,76:
– Hypopigmentation of skin and hair due to altered
melanogenesis
– Altered sweating and intolerance to heat
• Bone marrow4:
– Anaemia
– Coagulopathy due to dysfunctional platelets
Diagnosis
The clinical diagnosis of cystinosis is symptom-based and is
conﬁrmed by biochemical and molecular diagnosis.
Clinical diagnosis
Guiding signs are early-onset of severe Fanconi syndrome and
the detection of corneal crystals. As the disease progresses,
systemic involvement may be observed (Fig. 1). However, in
patientswith less severe forms, renal involvement is restricted
to proteinuria and CKD. Occasionally, corneal crystals in adult
patients with CKD of unknown aetiology lead to the diagno-
sis of cystinosis.25 Kidney biopsy, while not a requirement for
the diagnosis of cystinosis, can be useful in these atypical
presentations.2,16,24,32
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Table 2 – Biochemical diagnosis and WBC cystine level monitoring. Molecular diagnosis (www.orpha.net).
Requirements for WBC cystine level monitoring77–79
Sampling conditions No fasting required
In treated patients, blood extraction should be made 6h
post-cysteamine dose
Collect within lithium or sodium heparin tube
Ship immediately to the laboratory: it should be processed into 24
hours post-sampling
Keep at room temperature
Minimum volume For patients <10kg body weight: 6mL blood
For patients ≥10kg body weight: 10mL blood
RECOMMENDATIONS for monitoring WBC cystine levels At the start of Cystagon® treatment
Monthly after dose adjustments
Every 6 months in stable patients
Increase frequency in cases of signiﬁcant clinical changes
(Transplantation and Dialysis)
Reference Laboratory in Spain
Hospital Clínic de Barcelona
Servicio de Bioquímica y Genética Molecular. Sección de Errores Congénitos del Metabolismo
Dra. Judit García Villoria: jugarcia@clinic.ub.es
Tfn. 93 227 56 00 Ext. 7585
C/ Mejía Lequerica s/n. Ediﬁcio Helios III. Planta baja. 08028 Barcelona, Spain.
Requirements for the molecular diagnosis of CTNS gene12,13,15,80
Genetic testing of patient and family
Sample
2–3mL blood in EDTA at room temperature
DNA at room temperature
Prenatal testing
Sample DNA from cultured amniocytes or chorionic villi sampling
Prior identiﬁcation of the disease-causing mutations in parents and in index case
Previous appointment with the laboratory is essential
Reference Laboratory in Spain
Hospital Clínic de Barcelona
Servicio de Bioquímica y Genética Molecular. Sección de Errores Congénitos del Metabolismo
Dra. MaJosep Coll: mjcoll@clinic.ub.es
na, S
Tfn. 93 227 9341
C/ Mejía Lequerica s/n. Ediﬁcio Helios III. Planta baja. 08028 Barcelo
General biochemical diagnosis
This diagnosis is based on the detection of water/electrolyte
disorders, affected acid-base balance and eventually renal
function, which are all prototypical of Fanconi syndrome.24,28
Speciﬁc biochemical diagnosis
This involves the detection of elevated white blood cells
(WBC) cystine levels.77 Currently High Performance Liquid
Chromatography–Tandem Mass Spectrometry (HPLC-MS/MS)
in granulocytes is used as it is a more sensitive technique.78,79
The reference values are:
• healthy individual:≤0.5nmol 1/2 cystine/mgprotein (values
>0.5 may have diagnostic signiﬁcance, and it is recom-
mended to repeat the determination)• affected individual without treatment: >1nmol 1/2 cys-
tine/mg protein (usually >2)
• individual treated with good therapeutic control: ≤1 nmol
1/2 cystine/mg proteinpain.
Normal WBC cystine levels in newborns do not completely
rule out the diagnosis. Therefore, in cases where cystinosis is
highly suspected, a second test is recommended 3–6 months
after the ﬁrst study when the results are not conclusive79
(Table 2).
Molecular diagnosis
Cystinosis is conﬁrmed by the detection of homozygous or
compound heterozygous mutations in the CTNS gene. More
than 100 differentmutations have been reported and themost
frequent one is the ∼57kb deletion affecting the ﬁrst 10 exons,
especially in patients of Northern European descent. Speciﬁc
mutations turn into an absence of protein or a probably non-
functional truncated protein11,12,14,15,80 (Table 2).
Genetic counsellingSince cystinosis is an autosomal recessive disease, the proba-
bility of a family with one affected child having another with
cystinosis is 25%.81 In this case, genetic counselling includes
information on prenatal diagnostic techniques and embryo
nefrolog ia. 2015;35(3):304–321 311
Table 3 – Speciﬁc treatment with cysteamine.
Oral Cysteamine – Cystagon®31,47,92,93,94,102
Dosage
By age Children ≤12 years Patients >12 years
Recommended dosage by body surface area (g/m2/day) if weight > 50 Kg
(Dosage should be divided 4 times daily) 1.30g/m2/day 2g/day
Starting dosage 1/4 to 1/6 of the recommended dosage
Increase gradually over 4–6 weeks to avoid intolerance**
Dosage adjustments Raise if adequate tolerance and WB C cystine level is greater than
> 1nmol ½ cystine/mg protein
Maximum dosage 1.95g/m2/day
Overdosing is not recommended since it does not improve the prognosis and is associated
with adverse effects47
Renal insufﬁciency No dose adjustment required
RECOMMENDATIONS for appropriate
dosage
Treatment should be initiated under the supervision of a physician experienced in
the treatment of cystinosis
4 doses per day; every 6 hours; night dose included
Adjust the dose according to WBC cystine levels
Hard capsules should not be administered to children under the age of 6 years
owing to risk of aspiration
If needed, open the capsules and sprinkle the content on food
Cysteamine powder could be mixed with milk, potatoes and other starch-based
products. Avoid acidic drinks.
CYSTAGON® should be restarted after renal transplant to prevent non-renal
complications
Side effects Gastrointestinal disorders due to gastric acid hypersecretion
RECOMMENDATIONS for improving gastrointestinal tolerability:
Concomitant administration of proton pump inhibitors102
Administer with meals or immediately afterwards. Intake is recommended with food such as
milk, potatoes or other starchy foods92–94
Characteristic body odour and halitosis
RECOMMENDATIONS for improving halitosis: mentholated pills31
Other adverse reactions refer to SMPC92–94
Drug interactions No interaction studies have been conducted
Can be administered in conjunction with electrolytic or mineral supplements,
vitamin D analogues, tyrosine or immunosuppressive drugs
Cysteamine eye drops37–39,105–109
soluti
/day
s
i
f
a
p
d
T
S
T
cEye drops 0.55% cysteamine
Dose 1 drop/eye
Dosage 10–12 instillations
election.82,83 The probability of a woman with cystinosis hav-
ng an affected child is very low, except in consanguineous
amilies or endogamous populations. Males with cystinosis
re universally sterile.49
Genetic counselling usually includes information on
atient associations84–86 and institutional strategies in rare
iseases.87
reatmentymptomatic treatment of kidney involvement
he aim of treatment (Table 1 & Annex 1) is to control Fan-
oni syndrome, its complications and other factors involvedon (see Annex 1)
in kidney failure progression.24–28 In ESRD, promoting KTx is a
priority. Regardless of kidney involvement, all patients should
receive speciﬁc treatment with cysteamine for the prevention
and therapeutic control of the systemic disease.
Treatment of CKD should follow international
guidelines.88–90 In transplanted patients, minimising or
avoiding corticosteroids use is recommended.23
Speciﬁc treatment with cysteamineOral cysteamine
The speciﬁc treatment for all clinical forms of cystinosis is oral
cysteamine. Cysteamine depletes lysosomal cystine content
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Table 4 – Recommendations for improving treatment
compliance.7,9,10,114–119
Identify risk factors that affect adherence and apply corrective measures
when possible:
Intrinsic patient and socio-economic factors
Disease-related factors
Treatment-related factors
Healthcare system organisation barriers
Identify and assign a “Patient health Coordinator”
Promote patient education and treatment support:
Implement disease education programmes
Establish treatment programmes: easy to follow with support
measures for compliance
Use questionnaires to detect non-compliance
Follow-up of appointments and absences
Develop patient support programmes involving family members, friends
and patient associations
the degree to which patient behaviour follows the recommen-Create a multidisciplinary medical team
Implement protocols for transition to adult care
by forming disulphide cysteine–cysteamine complexes able to
exit the lysosomes by means of the alternative lysine channel,
and the remaining cysteine via a cysteine carrier.3,19,91
The ﬁrst speciﬁc pharmacological treatment for cystinosis
is Cystagon® (oral cysteamine bitartrate in hard capsules),
the only authorised therapy in Spain92–94. A new formula in
hard gastro-resistant capsules has recently been approved for
cysteamine.93–96
Therapeutic beneﬁts
Oral cysteamine should be initiated at the time of diagno-
sis and continued lifelong. When compliance is consistent,
cysteamine is able to deplete up to 95% of cellular cys-
tine deposits.62 The reduction in these deposits correlates
with cystinosis severity.32 It has been demonstrated that
cysteamine prolongs the life of the patient, while delaying kid-
ney disease progression and the need for renal replacement
therapy.5,97 Similarly, it reduces the severity and frequency
of extrarenal complications.32 Prognosis of the disease is
directly related to early treatment and its duration. Even
when cystinosis diagnosis is delayed, cysteamine has demon-
strated clinical beneﬁts.4,6,98 Although Fanconi syndrome is
not usually reversible with cysteamine,19 in some isolated
cases of prenatal diagnosis the beginning of cysteamine ther-
apy within the ﬁrst weeks of life prevented the appearance of
tubulopathy.99,100
Cystagon®: dosage, administration and treatment
monitoring
Treatment is based on the depletion of lysosomal cystine con-
tent which, in clinical practice, means the reduction of WBC
cystine levels, with an optimal therapeutic goal <1nmol hemi-
cystine/mg of protein. The decrease in those WBC cysteine
levels correlates with plasma cysteamine concentrations for
the 6 hours following Cystagon® dose, being minimum at ∼2h
after the drug is taken and returning to baseline (pre-dose)
6h later. This explains the need to take the drug every 6h,
overnight dose included101,102 (Table 3).
Monitoring of WBC cysteine levels at the start of treat-
ment and monthly after changes in the prescribed dosage is;35(3):304–321
recommended. In patients with maintained cystine lev-
els, follow-up controls are recommended every 6 months.
Similarly, in an individualised manner, the frequency of mon-
itoring should be increased in case of signiﬁcant clinical
changes such as KTx and dialysis77,78,79 (Table 2).
Oral treatment in special situations
Chronic kidney disease, dialysis and transplantation
Since there is no correlation between GFR and plasma cys-
teamine levels, it is not necessary to adjust the dosage to renal
function; instead, the prescribed dosage should be adjusted
to the quantiﬁcation of WBC cystine levels. Adjustments for
Fanconi syndrome are also unnecessary.6,103
Pregnancy and breastfeeding
Although data is insufﬁcient, reproductive toxicity and
teratogenic effects of cysteamine have been observed in
animals.104 Its use is therefore contraindicated during preg-
nancy, particularly in the ﬁrst trimester. Family planning
is recommended in women of childbearing age. Further-
more, cysteamine administration should be avoided during
breastfeeding.
Cysteamine eye drops
Speciﬁc treatment of ocular involvement in cystinosis
requires, in addition to oral cysteamine, the use of cysteamine
eye drops. The ophthalmological therapeutic strategy32,37
makes a distinction between:
Corneal involvement
Cystine crystal deposits should be treated with topical
cysteamine since the cornea is an avascular structure
and, consequently, oral medication is not effective for the
cornea.37,38,105,106 The recommended prescription is shown
in Table 3. Viscous formulae are being developed to achieve
longer contact of cysteamine with the ocular surface and
be able to reduce the frequency of instillations with equal
efﬁcacy.107,108
Involvement of non-corneal structures
Oral cysteamine is effective in the retina and other ocular
structures. The incidence of retinopathies has decreased with
the systemic use of cysteamine. The frequency and severity of
non-corneal manifestations are directly related to compliance
with oral cysteamine treatment, and the risk of important
vision loss may arise if systemic treatment is not correctly
followed.39,109
Compliance with speciﬁc cysteamine treatment
The World Health Organization (WHO) deﬁnes compliance asdations of medical professionals.110
The impact of non-adherence in cystinosis results in poorer
prognosis and faster progression of the renal and extrarenal
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Table 5 – Recommendations for follow-up of patients on renal replacement therapy (RRT): dialysis (D) and transplantation
(TxR).
Recommendations for dialysis6,103
Promote preventive KTx as an initial method of RRT in patients with advanced CKD
Monitor residual urine volume and urinary saline loss to adapt the dialysis prescription and avoid excessive ultraﬁltration
Maintain the general treatment of Fanconi syndrome and adapt the diet in an individual manner
Carefully monitor extrarenal involvement on a multidisciplinary basis
Oral and ophthalmological cysteamine treatment must be maintained
Cysteamine dosage should not be adjusted to glomerular ﬁltration rate (see Speciﬁc Treatment with Cysteamine section)
Recommendations for kidney transplantation4–6,33,88–90
Prior to waiting list inclusion
Promote preventive kidney transplantation when the glomerular ﬁltrate ≤20mL/min/1.73 m2
Living or deceased donor
Evaluate the associated Fanconi syndrome (residual diuresis – can be very high – saline loss, rickets, tubular acidosis, carnitine
deﬁciency)
Monitor WBC cystine levels and optimise treatment with cysteamine (oral and ophthalmological)
Assess possible systemic involvement and its impact on the transplant (hypothyroidism, diabetes, cardiovascular disease, bone
disease, swallowing disorders)
Prescribe ﬂuids and individualised diet. Assess phosphate, potassium, bicarbonate and carnitine supplement requirements
Pre-transplant and peri-transplant
Avoid volume depletion before and during surgery (intensive endovenous ﬂuid therapy to guarantee normovolaemia, including
potassium and bicarbonate supplements)
Immunosuppression according to hospital protocol
Temporary suspension of cysteamine treatment
Immediately post-transplant
Administer ﬂuid therapy and sufﬁcient electrolytes to maintain adequate water/electrolyte balance and good control of residual
Fanconi syndrome
Monitor the possible appearance of diabetes.
Immunosuppression therapy according to hospital protocol
Continued post-transplant care
Reintroduce cysteamine once the patient and graft are stable, approximately 3–4 weeks post-transplantation, at increasing doses up to
therapeutic doses
Monitor WBC cystine levels
Immunosuppression following hospital protocol; promote reduction in and/or suspension of corticosteroids
Controls and follow-up in accordance with recommendations and clinical guidelines
Maintain ophthalmological treatment with cysteamine and stimulate treatment compliance
Assess possible systemic involvement and its impact on transplantation. Promote and standardise a multidisciplinary health care plan
for cystinosis
In any clinical situation, it is necessary to administer speciﬁc cystinosis treatment with oral cysteamine to maintain recommended WBC cystine
levels <1nmol hemicystine/mg protein and cysteamine eye drops to eliminate corneal deposits (see Table 3).
Table 6 – Recommendations for ophthalmological follow-up.4,37–39,105–109,120
Test Ocular structure Frequency Observations
Slit lamp
biomicroscopy
Study of the cornea and rest of anterior
segment
Annual
Intraocular pressure
measurement
Rule out ocular hypertension Annual
Dilated fundus
examination
Assess optic disc and retinal
pigmentation
Annual Urgent: if the patient reports
severe loss of VA (uncommon)In patients with GH, do a baseline
assessment and after 4 months to detect
intracranial hypertension120
Photopic and
scotopic ERG
Functionality of rods and cones Only if patient reports altered night vision
or abnormal retinal examination
Equipment Slit lamp*
Tonometer
Indirect ophthalmoscope
In any clinical situation, speciﬁc cystinosis treatment is required with oral cysteamine to maintain recommended WBC cystine levels
<1nmol hemicystine/mg protein and cysteamine eye drops to eliminate corneal deposits (See Table 3).
ERG: electroretinogram; GH: growth hormone; VA: visual acuity.
∗ Very sensitive for diagnosing cystine crystals in the cornea, but less useful for patient follow-up since the quantiﬁcation of crystals is rather
subjective. It is therefore interesting to record detailed data at each examination on the distribution of crystals in the cornea, specifying
whether the deposition is only peripheral or diffuse and whether they are located in the epithelium, stroma and/or endothelium.
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Table 7 – Recommendations for the follow-up and treatment of endocrine system involvement.4,5,32,48,49,121
Disorder Complementary studies Frequency Treatment Observations
Hypothyroidism TSH, T4L, Anti-thyroid
Ab/Imaging study not
necessary
At diagnosis Levothyroxine Initiate treatment when
TSH > 10 mIU/L/if there
are symptoms, consider
initiating with TSH, 5–10
mIU/L
TSH, T4L Routine follow-up:
Quarterly for dosage
adjustments/annual, if
TSH is normal
Diabetes Mellitus Glycaemia, HbA1c (optional:
c-peptide)
Diagnosis Insulin If pancreatic reserve is
sufﬁcient, consider
single daily dose of
slow-release insulin
If symptoms of
polyuria-polydypsia:
laboratory tests with
ionogram, venous blood
gases and ketonuria
Glycaemia, HbA1c Quarterly or biannual
follow-up, according to
clinical criteria/annual, if
no symptoms
Lipid proﬁle: total
cholesterol, LDL, HDL and TG
Annual Dyslipidaemia
treatment
Funduscopy Annual According to
ophthalmolo-
gist
criteria
Pain and vibration sensitivity Annual Education to
prevent
lesions
Examination feet and pulse Annual
Impaired longitudinal
growth
Nutritional assessment According to clinical
criteria
Optimise
nutrition
Consider
supplements and
referral to
nutritionist
Height and weight At each visit Until bone
maturity
See Fanconi syndrom section Treatment of
Fanconi
syndrome
Bone age Diagnosis r-GH In pubescent patients,
rule out hypogonadism/in
transplant recipients,
consider withdrawal or
reduction of
corticosteroids
GH, IGF-1, IGFBP-3
If no kidney failure: GH
secretion studies
Bone age, IGF-1 Annual follow-up
Funduscopy Before initiating GH and
after 3–4 months under
treatment
Intracranial
hypertension
secondary to GH
usually occurs at
the start of
treatment (mean:
3–4 months)
Urgent if headache or
reduced vision
Calcium, phosphorus,
alkaline phosphatase,
25OH·D3, PTH
Annual Vitamin D, if
deﬁciency
Rule out rickets
and vitamin D
nutritional
deﬁciency
Calcitriol, if
kidney failure
Bone mineral density In adulthood; to be
assessed according to
results.
If there is
osteoporosis,
consider
speciﬁc
treatment
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Table 7 – (Continued)
Disorder Complementary studies Frequency Treatment Observations
Hypogonadism Physical exam: sexual
maturation and
secondary sexual
characteristics
At each visit During puberty
period until
complete
maturity
Testosterone, SHBG, LH,
FSH+assessment of
thyroid function (see
above)
Diagnosis Daily
testosterone
replacement
therapy
(TRT): Topical
(if panic to
injections), or
IM (if
compliance
problems)
If low
testosterone
with normal LH
and FSH levels:
MRI of pituitary
T, LH, FSH Annual follow-up
Fertility Semen analysis Diagnosis Infertility is a
constant feature
in affected males
Consider high-risk
pregnancy
Suspend oral
cysteamine
during gestation
In any clinical situation, speciﬁc cystinosis treatment is required with oral cysteamine treatment to maintain recommended WBC cystine
levels <1nmol hemicystine/mg protein and topical cysteamine to eliminate corneal deposits.
25OHD3: 25-hydroxycholecalciferol (calcifediol); FSH: follicle-stimulating hormone; GH: growth hormone; HbA1c: glycated haemoglobin; IGF-
1: insulin-like growth factor 1; IGFBP3: insulin-like growth factor-binding protein 3; LH: luteinising hormone; PTH: parathyroid hormone;
bulin
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units in cystinosis. Our aim was to provide support tools andrGH: recombinant growth hormone; SHBG: sex hormone-binding glo
stimulating hormone.
isease in patients who are non-compliant compared with
hose who are.5,6,97
Information on adherence in patients with cystinosis is
imited, although monitoring WBC cystine levels is able to
etect non-compliant patients.77,79 Other studies have con-
rmed adequate adherence to Cystagon® in children patients
hich wanes signiﬁcantly in adolescents and adults.7,8
onetheless, in groups of highly motivated patients, only 8%
ad compliance problems.111
In cystinosis, risk factors for non-compliance with cys-
eamine therapy include: dosage schedules, problems with
olerance, side effects and the requirements of several med-
cations for the control of the clinical manifestations of
he disease. Moreover, other risk factors which are not
xclusive to cystinosis are: limited knowledge of the dis-
ase, lack of motivation, inadequate transition of patients
o adult care units and impact of the disease on quality of
ife.7,9,10Nevertheless, suboptimal treatment compliance is not a
henomenon restricted to cystinosis. Recent studies report
hat 52 to 67% of adult kidney transplant recipients do not
orrectly follow prescribed immunosuppressant treatment,; T: testosterone; T4: free thyroxine; TG: triglycerides; TSH: thyroid-
which increases the probability of graft loss.112,113 These
percentages are similar to those published in patients with
cystinosis in our population,7 which may indicate the coex-
istence of scenarios in common with CKD. Therefore, in
order to improve adherence in cystinotic patients, the recom-
mended strategy is to correct risk factors for non-compliance
and promote patient self-care, similar to the strategies
used successfully in adult kidney transplant recipients114–119
(Table 4).
Recommendations for the follow-up and
treatment of patients with cystinosis
T-CiS.bcn group members, after an exhaustive review of med-
ical literature and based on our clinical practice with patients,
have stablished recommendations for the multidisciplinary
care and connected transition from paediatric to adult-caremedical advice to health care professionals involved and inter-
ested in the care of cystinosis.
These recommendations are presented in Tables 4–8.
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Table 8 – Recommendations for the follow-up and treatment of neurological involvement.4,52–73,122–126
Disorder Evaluation Complementary studies Frequency Treatment Observations
Motor functions of the
skeletal muscles4,52,53
Degree of muscle
atrophy/disease
progression/degree of
disability
MRC scale Annual Rehabilitation Use validate
instruments
Quantitative
determinations of
hand muscle strength
(Jamar dynamometer,
Martin vigorimeter
and Jamar Hydraulic
Pinch Gauge)
Annual
Electromyography According to clinical
criteria
Muscle MRI According to clinical
criteria
Muscle biopsy According to clinical
criteria
Orofacial motor function
(language) and
swallowing58,122,123
Facial and bulbar
muscles: strength and
range of movement of
lips, tongue, soft palate,
jaw and facial muscles
in phonation,
articulation, swallowing,
breathing and
expressions
Focused physical
examination
Annual Reeducation if early
signs of dysphagia are
detected to prevent
bronchoaspirates
Video ﬂuoroscopy According to clinical
criteria
Objective: to asses
different phases of
swallowing and
movement of food
bolus within the oral
cavity and its passage
through the
esophagus
Respiratory muscle
function124
Presence of dyspnoea,
apnoea and/or snoring
during sleep, morning
headaches, daytime
hypersomnia, decreased
coughing capacity or
increased anomalies in
expectoration
Spirometry Annual Symptomatic
respiratory
physiotherapy,
ventilatory support
(CPAP/BIPAP)
Especially in patients
with swallowing
disorders, risk of
bronchoaspirtion or
who present
symptoms of
neuromuscular
respiratory
insufﬁciency
Oxygen saturation
Arterial blood gas
Annual
Polysomnography Annual
Central nervous
system54–57,59–68,125,126
Signs of involvement
(headache, episodes of
unconsciousness, poor
school performance,
decline in cognitive
functions, behavioural
alterations, etc.)
Focused physical
examination
Neurophysiological
studies Neuroimaging
Annual Directed to underlying
disorder
Complementary tests
if anomalies are
detected
According to clinical
criteria
According to clinical
criteria
Neurocognitive
alterations69–73
Neuropsychological
examination
Speciﬁc evaluation
questionnaires for
overall cognitive
performance,
attention and
executive functions,
language, memory;
perceptive,
visuospatial and
visuoconstructive
functions; voluntary
cognitive motor
control
Annual Directed to underlying
disorder
Adapted to patient’s
age (school children
and adults)
In any clinical situation, speciﬁc cystinosis treatment is required with oral cysteamine treatment to maintain recommended WBC cystine levels <1nmol
hemicystine/mg protein and topical cysteamine to eliminate corneal deposits.
MRI: magnetic resonance imaging, CPAP: Continuous Positive Airway Pressure, BIPAP: biphasic positive airway pressure.
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ANNEX 1.a – Supplements, drugs and pharmaceutical formula
Drug Brand name/Produc
Alkaline sup
Sodium bicarbonate Sodium bicarbonate Torres Mun˜oz 500m
Sodium bicarbonate Torres Mun˜oz 60 g;
Sodium bicarbonate Serra 180 g (powder
Sodium bicarbonate Viviar 210 g; 250 g; 5
Sodium bicarbonate NM 1 g; 2 g (sachet)
*Sodium bicarbonate 1M (8,4%) solución
Sodium citrate *Bicitra oral solution
Potassium citrate *Polycitra oral solution
*Polycitra LC with phosphrous-oral solut
Potassium su
Potassium ascorbate Boi-K (20 effervescents tablets)
Bok-K Aspártico (20 effervescents tablets
Potassium chloride Potasion 600 mg (60 cap.s)
Potassium glucoheptonate Potasion 1,32 g/5 mL (125 mL; 250 mL)
Phosphorus su
Sodium Phosphate *Phosphorus oral solution or Joulie Solut
Phosphate Sandoz 500mg (100 cap.)
Sodium Phosphate monobase NM (100 s
*Polycitra LC with phosphrous-oral solut
Othe
Carnitine Carnicor 1.5 g/5 mL (40 mLoral solution)
Carnicor 1 g drinkable vials (10 mL)
Secabiol 300mg/mL (40 mL oral solution
Indomethacin Artinovo 25mg (30 cap.)
Flogoter 25mg (40 cap.)
Inacid 25mg (30 cap.)
Indonilo 25mg (24 cap.)
*Indomethacin 2 mg/mL oral solution
Cysteamine *Cysteamine 0,55% eye drop solution
cap.: capsules, *: magistral formulation.(3):304–321 317ANNEX1a.
tions prescribed in cystinosis
t Content
plements
g (30 cap.) 500 mg/comp.
200 g; 750 g (powder)
)
00 g (powder)
1 g/sachet; 2 g/sachet
oral 1mEq/mL
1mEq Bicarbonate/mL; 1mEq Na/mL;
0.5 mmol citrate/mL
2mEq Bicarbonate; 1mEq Na/mL;
1mEq K/mL; 1mmol Citrate/mL
ion 2mEq Bicarbonate; 1 mEq Na/mL;
1mEq K/mL; 1 mmol Citrate/mL;
0.6 mmol P/mL
pplements
1mEq K/tablet
) 25mEq K/tablet
8mEq K/tablet
1mEq K/mL
pplements
ion 1mmol P/ml (30.9mg P/ml)
16.1 mmol P/comp (500 mg P/comp.)
achets) 26mmol P/sobre (800 mg P/sachet)
ion 2mEq Bicarbonate; 1 mEq Na/mL;
1mEq K/mL; 1mmol Citrate/mL;
0.6mmol P/mL)
rs
300mg/mL carnitine
100mg/mL carnitine
) 300mg/mL carnitine
25mg indomethacin
25mg indomethacin
25mg indomethacin
25mg indomethacin
2mg indomethacin
0.55% cysteamine
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Annex 1.b – Supplements, drugs and pharmaceutical formulations prescribed in cystinosis
Compounded formulations
Liquid formulation Component Amount
Sodium bicarbonate 1M (8.4%) oral solutiona Sodium bicarbonate 8.4 g
Sterile distilled water (qs) 100mL
Bicitra oral solutionb Sodium, citrate 2H2O (Tri-) 10 g
Monohydrated citric acid 6.7 g
Simple syrup with preservatives 50mL
Sterile distilled water 40mL
Polycitra oral solutionb Potassium, citrate H2O (Tri-) 11 g
Sodium, citrate 2H2O (Tri-) 10 g
Monohydrate citric acid 6.7 g
Simple syrup with preservatives 50mL
Sterile distilled water 38mL
Polycitra LC with phosphorus, oral solutionc Sodium hydrogenophosphate-12 1.4 g
Phosphoric acid 85% 1.4mL
Sterile distilled water 32mL
Potassium, citrate H2O 11g
Sodium, citrate 10 g
Monohydrate citric acid 6.7 g
Simple syrup (qs) 100mL
Orange extract 1 drop
Indomethacin 2 mg/mL oral solutiond,e,f,g Indomethacin 0.2 g
Ethyl alcohol 0.7mL
Sterile distilled water 0.3mL
Simple syrup+Nipagin/nipasol 100mL
Phosphates, oral solution (Joulie solution)b Phosphoric acid 85% 5.45 g
Disodium phosphate 12 H2O (di) 18.72 g
Sterile distilled water (qs) 100mL
Cysteamine 0.55% eye drop solutionh Benzalkonium chloride 0.045 g
Sodium chloride 0.9% 225mL
Cysteamine hydrochloride 1.2375 g
a Trissel LA. Trissel’s Stability of Compounded Formulations. 3rd Ed. American Pharmacists Association, Washington DC; 2005:388–389.
b The United States Pharmacopeial convention. USP-Pharmacists’ Pharmacopeia, 2nd Ed., Rockville MD; 2008.
c Hospital Sant Joan de Déu, Servicio de Farmacia, Barcelona, 2014.
d DasGupta V et al. Stability of pediatric liquid dosage forms of ethacrynic acid, indomethacin, methyldopate hydrochloride, prednisone and
spironolactone. Am J Hosp Pharm 1978;35:1382–1385.
e Martindale. The complete Drug Reference, 33 Ed. Pharmaceuticals Press. Massachusetts. 2002;45.1.
f Atienza M, Vila MN. Formulación magistral en pediatría. 1◦Ed: Edika Med SL. Barcelona, 2005;118.
g The Hospital Sick Children, Department of Pharmacy, Toronto, 2000.
h Gahl WA, Kuehl EM, Iw ata F, Lindblad A, Kaiser-Kupfer MI et al. Corneal crystals in nephropathic cystinosis: natural history and treatment
with cysteamine eyedrops. Mol Genet Metab. 2000;71:100–120.
qs: quantum sufﬁciat (sufﬁecient quantity)
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